China Reform Holdings Co., Ltd. has led a RMB670 million (US$101 million) new funding round in 3D Medicines, a Chinese healthcare firm developing precision medicine for cancer treatment.
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech
Want to read this important story?
Access thousands of news articles and data posts over the past 9 years!
Already have an account or paid subscription?